Stay updated with breaking news from Ace2. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
As SARS-CoV-2 continues to evolve, new variants are expected to arise that may have an increased ability to infect their hosts and evade the hosts' immune systems.
70歲周先生原為自體免疫疾病雷諾氏症患者，今年5月因確診新冠肺炎，接受臺北醫學大學附設醫院治療，入院
.jpg)
According to new research by an international team of scientists, all SARS-CoV-2 variants, including variants of concern (VOC) Alpha, Beta, Gamma, and Delta, exhibit enhanced affinity toward recombinant human soluble ACE2.
.jpg)
A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.
.jpg)
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first emerged in Wuhan, China, in late December 2019, has quickly become the most urgent issue facing scientists worldwide. It has been reported that the respiratory infection causes cardiac dysfunction in 25-55% patients, including hospitalized patients and non-critical patients.